Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter- and intrapatient tumor heterogeneity

摘要

Personalized cancer therapy, based on molecular profiling of each patient's cancer, is increasingly viewed as likely to increase the overall effectiveness of cancer treatment and to do so in both a clinically meaningful and cost-effective manner by sparing patients who are unlikely to benefit from the costs and adverse effects of ineffective therapies. Thus, in the emerging era of new anticancer agents directed against molecular targets present in only a small subset of patients within a general population, such as non-small-cell lung cancer (NSCLC), it is increasingly important to consider simultaneous and early codevelopment of an associated predictive biomarker.